These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23728112)

  • 21. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy.
    Chiang CY; Zebaze RM; Ghasem-Zadeh A; Iuliano-Burns S; Hardidge A; Seeman E
    Bone; 2013 Jan; 52(1):360-5. PubMed ID: 23072919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bilateral atypical ulnar fractures occurring after long-term treatment with bisphosphonate for 7 years and with teriparatide for 2 years: a case report.
    Asano Y; Tajiri K; Yagishita S; Nakanishi H; Ishii T
    Osteoporos Int; 2020 Dec; 31(12):2473-2476. PubMed ID: 32910217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.
    Zanchetta MB; Diehl M; Buttazzoni M; Galich A; Silveira F; Bogado CE; Zanchetta JR
    J Bone Miner Res; 2014 Apr; 29(4):999-1004. PubMed ID: 24115250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users.
    Lee SH; Lee YH; Suh JS
    AJR Am J Roentgenol; 2017 Oct; 209(4):867-873. PubMed ID: 28796551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pathogenesis of atypical femoral fracture].
    Iwata K; Mashiba T
    Clin Calcium; 2016 Jan; 26(1):73-9. PubMed ID: 26728533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Femur fractures caused by long-term bisphosphonate therapy].
    Somford MP; Thomassen BJ; Draijer WF
    Ned Tijdschr Geneeskd; 2010; 154():A1218. PubMed ID: 20619008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical forearm fractures associated with long-term use of bisphosphonate.
    Moon J; Bither N; Lee T
    Arch Orthop Trauma Surg; 2013 Jul; 133(7):889-92. PubMed ID: 23619919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.
    Patel VC; Lazzarini AM
    Orthopedics; 2010 Oct; 33(10):775. PubMed ID: 20954650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy.
    Gu KD; Ettinger B; Grimsrud CD; Lo JC
    Osteoporos Int; 2021 Oct; 32(10):2119-2123. PubMed ID: 33914104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural, densitometric and biomechanical evaluations of Chinese patients with long-term bisphosphonate treatment.
    Leung KS; Tang N; Griffith J; Choy TK; Hung VW; Mok HW; Shi L; Leung PC; Cheung WH
    Chin Med J (Engl); 2013 Jan; 126(1):27-33. PubMed ID: 23286473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare non-traumatic periprosthetic femoral fracture with features of an atypical femoral fracture: a case report.
    Niikura T; Lee SY; Sakai Y; Kuroda R; Kurosaka M
    J Med Case Rep; 2015 May; 9():103. PubMed ID: 25943378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Is SSBT associated with atypical femoral fracture? SSBT is associated with atypical femoral fracture - pathophysiology of atypical femoral fractures - ].
    Mashiba T
    Clin Calcium; 2012 Jun; 22(6):914-8. PubMed ID: 22653033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Atypical subtrochanteric femur fracture under alendronate therapy in spite of an intramedullar implant].
    Sobotta HP; Gösling T
    Unfallchirurg; 2017 Feb; 120(2):171-175. PubMed ID: 27812727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [SSBT (severely suppressed bone turnover) ].
    Mori S
    Clin Calcium; 2013 Mar; 23(3):365-70. PubMed ID: 23445889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Wada Y; Nakatsue T; Iguchi S; Fujisawa J; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I
    Osteoporos Int; 2016 Mar; 27(3):1217-1225. PubMed ID: 26519417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
    Gopal GK; Tam KL; Krishnan SP; Maddern IL
    N Z Med J; 2014 Feb; 127(1389):81-5. PubMed ID: 24548959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.
    Meier RP; Perneger TV; Stern R; Rizzoli R; Peter RE
    Arch Intern Med; 2012 Jun; 172(12):930-6. PubMed ID: 22732749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.
    Somford MP; Draijer FW; Thomassen BJ; Chavassieux PM; Boivin G; Papapoulos SE
    J Bone Miner Res; 2009 Oct; 24(10):1736-40. PubMed ID: 19419297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonate-related complete atypical subtrochanteric femoral fractures: diagnostic utility of radiography.
    Rosenberg ZS; La Rocca Vieira R; Chan SS; Babb J; Akyol Y; Rybak LD; Moore S; Bencardino JT; Peck V; Tejwani NC; Egol KA
    AJR Am J Roentgenol; 2011 Oct; 197(4):954-60. PubMed ID: 21940585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment with bisphosphonates and atypical fractures].
    Spivacow FR; Sarli M; Buttazzoni M
    Medicina (B Aires); 2009; 69(6):612-8. PubMed ID: 20053599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.